等待开盘 09-17 09:30:00 美东时间
-1.290
-1.23%
Axcelis Technologies (NASDAQ:ACLS) has outperformed the market over the past 5 years by 5.42% on an annualized basis producing an average annual return of 16.86%. Currently, Axcelis Technologies has a market capitalization of $3.28 billion. Buying $100 In ACLS: If an investor had bought $100 of ACLS...
09-14 23:30
BEVERLY, Mass., Sept. 8, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, today annou...
09-08 20:00
BEVERLY, Mass., Sept. 1, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced t...
09-01 20:00
Axcelis Technologies (NASDAQ:ACLS) has outperformed the market over the past 5 years by 8.39% on an annualized basis producing an average annual return of 19.5%. Currently, Axcelis Technologies has a market capitalization of $3.80 billion. Buying $100 In ACLS: If an investor had bought $100 of ACLS ...
08-27 00:45
华盛资讯8月7日讯,Axcelis Technologies, Inc.公布2026财年Q2业绩,公司Q2营收2.15亿美元,同比增长10.6%,归母净利润0.23亿美元,同比下滑25.8%。
08-07 11:33
Axcelis Technologies (NASDAQ:ACLS) has outperformed the market over the past 15 years by 11.14% on an annualized basis producing an average annual return of 24.44%. Currently, Axcelis Technologies has a market capitalization of $4.38 billion. Buying $1000 In ACLS: If an investor had bought $1000 of ...
08-07 00:00
Axcelis Technologies (NASDAQ:ACLS) reported quarterly earnings of $1.06 per share which beat the analyst consensus estimate of $0.89 by 19.1 percent. This is a 6.19 percent decrease over earnings of $1.13 per share from the same period last year. The company reported quarterly sales of $215.175 mill...
08-06 19:03
System qualified for emerging PMIC device application requiring advanced 15 MeV implant capability BEVERLY, Mass., July 28, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a ...
07-28 20:00
Crinetics Pharmaceuticals涨96.69%;费哲金融服务涨4.46%;库珀医疗涨3.64%
07-07 15:01
今日重点评级关注:摩根士丹利:维持杜邦"标配"评级,目标价从52美元升至156美元;蒙特利尔银行:维持Taysha Gene Therapies"跑赢大市"评级,目标价从10美元升至14美元
06-24 14:08